Clinical Trials Logo

Clinical Trial Summary

To assess the safety and tolerability of HRS2543 in patients with advanced tumors and to determine the recommended phase II dose (RP2D) of HRS2543


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05068856
Study type Interventional
Source Shanghai Hengrui Pharmaceutical Co., Ltd.
Contact Jie Xie, M.M.
Phone +021-61053363
Email jie.xie@hengrui.com
Status Recruiting
Phase Phase 1
Start date December 28, 2021
Completion date August 31, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT06245122 - A Study of CS23546 in Subjects With Advanced Tumors Phase 1
Not yet recruiting NCT06314087 - iTAPVR Study - Phase II Randomized Study Phase 2
Recruiting NCT05390528 - A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma Phase 1/Phase 2
Completed NCT02419417 - Study of BMS-986158 in Subjects With Select Advanced Cancers Phase 1/Phase 2
Completed NCT04808453 - Phase I Study of CPI-300 in Patients With Advanced Tumors Phase 1
Recruiting NCT05799183 - A SHR-1210 BE Study on Healthy Subjects Phase 1
Recruiting NCT05429008 - A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm Phase 1
Terminated NCT04198818 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors Phase 1/Phase 2
Not yet recruiting NCT05213767 - Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advanced Malignant Tumors Phase 1
Not yet recruiting NCT04151810 - Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors Phase 1
Completed NCT03781362 - Study of CPI-100 in Patients With Advanced Tumors Phase 1
Recruiting NCT03908814 - Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors Phase 1
Recruiting NCT05061628 - The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor Phase 1
Recruiting NCT05867771 - A Study of PM1022 in Patients With Advanced Tumors Phase 1/Phase 2
Recruiting NCT03444714 - Phase I Study of RiMO-301 With Radiation in Advanced Tumors Phase 1